Non-small-cell lung cancer (NSCLC) is a leading cause of cancer deaths worldwide. Crizotinib has beenapproved by the U.S. Food and Drug Administration for the treatment of patients with advanced NSCLC.However, understanding of mechanisms of action is still limited. In our studies, we confirmed crizotinib-inducedapoptosis in A549 lung cancer cells. In order to assess mechanisms, small molecular docking technology wasused as a preliminary simulation of signaling pathways. Interesting, our results of experiments were consistentwith the results of computer simulation. This indicates that small molecular docking technology should findwide use for its reliability and convenience.